Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Mirabegron
Drug ID BADD_D01475
Description Mirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. It is unique amongst overactive bladder treatment options in that, unlike other treatments such as [solifenacin] and [darifenacin], it lacks significant antimuscarinic activity,[A232553] which is responsible both for the therapeutic effects of these medications and their broad range of adverse effects. Mirabegron has a comparatively favorable adverse effect profile as compared to other available treatment options, and its complementary mechanism to the antimuscarinics that came before it allows for its use alongside solifenacin in refractory cases.[L32853] Mirabegron first received FDA approval in 2012, under the brand name Myrbetriq, for the treatment of adults with overactive bladder.[L32853] An extended-release granule formulation was subsequently granted approval in March 2021 for the treatment of pediatric patients with neurogenic detrusor overactivity.[L32853] Mirabegron is also used in other jurisdictions across the globe, including Canada,[L32925] the EU,[L32945] and Japan.[A7469]
Indications and Usage Mirabegron is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Marketing Status Prescription
ATC Code G04BD12
DrugBank ID DB08893
KEGG ID D09535
MeSH ID C520025
PubChem ID 9865528
TTD Drug ID D0X5UN
NDC Product Code 0469-2602; 70518-3158; 0469-5020; 65977-0133; 55111-971; 14501-0031; 64552-4077; 66639-022; 55154-8713; 59285-004; 76072-1013; 65727-048; 59651-015; 65372-1202; 64552-4084; 65977-0112; 55111-961; 42765-047; 65085-0067; 55154-8712; 0469-2603; 14501-0092; 70518-2435; 66039-902; 0469-2601; 68259-1315
Synonyms mirabegron | Betmiga | 2-(2-aminothiazol-4-yl)-4'-(2-((2-hydroxy-2-phenylethyl)amino)ethyl)acetanilide | Betanis | YM 178 | YM-178
Chemical Information
Molecular Formula C21H24N4O2S
CAS Registry Number 223673-61-8
SMILES C1=CC=C(C=C1)C(CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Abdominal distension07.01.04.0010.000828%
Abdominal pain07.01.05.002--
Abdominal pain upper07.01.05.0030.001656%
Abnormal dreams19.02.03.001; 17.15.02.0010.001242%Not Available
Abnormal faeces07.01.03.0010.000828%Not Available
Agitation19.06.02.001; 17.02.05.0120.001656%
Alanine aminotransferase increased13.03.01.003--
Alopecia23.02.02.0010.002484%
Amnesia19.20.01.001; 17.03.02.0010.001242%
Angina pectoris24.04.04.002; 02.02.02.0020.001242%
Angioedema10.01.05.009; 23.04.01.0010.001242%Not Available
Anxiety19.06.02.002--
Arrhythmia02.03.02.0010.004139%Not Available
Arthralgia15.01.02.001--
Aspartate aminotransferase increased13.03.01.006--
Asthenia08.01.01.0010.004139%Not Available
Atrial fibrillation02.03.03.0020.003311%
Back pain15.03.04.005--
Benign prostatic hyperplasia21.04.02.0010.000828%Not Available
Bladder pain20.02.02.001--Not Available
Blister23.03.01.001; 12.01.06.0020.001242%Not Available
Blood bilirubin increased13.03.01.008--
Blood glucose decreased13.02.02.0010.000828%Not Available
Blood glucose increased13.02.02.0020.001242%Not Available
Blood lactate dehydrogenase increased13.04.02.002--
Blood pressure decreased13.14.03.0020.001242%Not Available
Blood pressure increased13.14.03.0050.014901%Not Available
Blood pressure systolic increased13.14.03.0060.001656%Not Available
Breast cancer21.05.01.003; 16.10.01.001--Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 7 Pages